A

Atossa Therapeutics
D

ATOS

0.61200
USD
-0.03
(-4.87%)
مفتوح الان
حجم التداول
402
الربح لكل سهم
-0
العائد الربحي
-
P/E
-3
حجم السوق
79,052,042
أصول ذات صلة
A
AVXL
-0.19500
(-2.35%)
8.10500 USD
B
BKYI
-0.02590
(-3.45%)
0.72410 USD
D
DVAX
-0.115
(-0.89%)
12.750 USD
G
GNPX
-0.10090
(-23.13%)
0.33540 USD
I
IBIO
-0.17000
(-4.47%)
3.63000 USD
I
INO
-0.03000
(-1.89%)
1.56000 USD
N
NVAX
-0.38500
(-6.44%)
5.59500 USD
V
VXRT
0.02690
(7.58%)
0.38200 USD
المزيد
الأخبار المقالات

العنوان: Atossa Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.